Symptom-based viral load testing should be considered for MSM

2011 ◽  
Vol 633 (1) ◽  
pp. 9-9
1999 ◽  
Vol 30 (2) ◽  
pp. 102-108
Author(s):  
Patricia Bereck Weikersheimer

2011 ◽  
Vol 14 (1) ◽  
pp. 23-23 ◽  
Author(s):  
Jane Greig ◽  
Philipp du Cros ◽  
Derryck Klarkowski ◽  
Clair Mills ◽  
Steffen Jørgensen ◽  
...  

2010 ◽  
Vol 201 (s1) ◽  
pp. S27-S36 ◽  
Author(s):  
Adrian Puren ◽  
Jay L. Gerlach ◽  
Bernhard H. Weigl ◽  
David M. Kelso ◽  
Gonzalo J. Domingo

2010 ◽  
Vol 14 (7) ◽  
pp. 852-858 ◽  
Author(s):  
M. Barton ◽  
S. Wasfy ◽  
D. Hébert ◽  
A. Dipchand ◽  
A. Fecteau ◽  
...  

1999 ◽  
Vol 123 (11) ◽  
pp. 1011-1014
Author(s):  
Frederick S. Nolte

Abstract Quantitative human immunodeficiency virus (HIV) type 1 RNA tests have been essential tools in increasing our understanding of HIV pathogenesis and antiretroviral therapy. The plasma HIV RNA level is among the most powerful predictive tests in modern medicine for disease progression and has rapidly become the standard of practice for guiding clinicians in initiating, monitoring, and changing antiretroviral therapy. In this article the scientific rationale and clinical indications for viral load testing in HIV infection are reviewed.


HIV ◽  
2020 ◽  
pp. 45-54
Author(s):  
Robert K. Bolan

It has been conclusively proven that sexual transmission of HIV does not occur if the individual living with HIV is adherent to antiretroviral therapy and HIV replication is consistently maintained below a plasma level of 200 copies/mL. What remains to be defined is the frequency of viral load testing to provide assurance that HIV is suppressed and how long must it remain so until suppression can be considered durable. This is required in order to provide guidance for HIV pre-exposure prophylaxis (PrEP) use by a sexual partner who is not living with HIV. Based on currently published studies and until more data are presented, it seems prudent to recommend that sexual partners of individuals living with HIV who are highly adherent to treatment use PrEP for 6 months to 1 year following initiation of HIV treatment and that viral load testing be performed quarterly for at least the first 2 years in the partner living with HIV.


2020 ◽  
Vol 23 (7) ◽  
Author(s):  
Elizabeth Zaniewski ◽  
Cam H Dao Ostinelli ◽  
Frédérique Chammartin ◽  
Nicola Maxwell ◽  
Mary‐Ann Davies ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document